Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis (IPF). Boehringer is in a race with InterMune, whose rival drug pirfenidone is already sold in Europe, but so far has struggled to catch on. Report